nab-paclitaxel for the management of patients with advanced non-small-cell lung cancerHIRSH, Vera.Expert review of anticancer therapy. 2014, Vol 14, Num 2, pp 129-141, issn 1473-7140, 13 p.Article

Skeletal morbidity in lung cancer patients with bone metastases: Demonstrating the need for early diagnosis and treatment with bisphosphonatesLANGER, Corey; HIRSH, Vera.Lung cancer. 2010, Vol 67, Num 1, pp 4-11, issn 0169-5002, 8 p.Article

Zoledronic Acid Use in Cancer Patients: More Than Just Supportive Care?COLEMAN, Robert; COOK, Richard; HIRSH, Vera et al.Cancer. 2011, Vol 117, Num 1, pp 11-23, issn 0008-543X, 13 p.Article

Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non-Small-Cell Lung CancerMANEGOLD, Christian; GRAVENOR, Donald; WOYTOWITZ, Donald et al.Journal of clinical oncology. 2008, Vol 26, Num 24, pp 3979-3986, issn 0732-183X, 8 p.Article

Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo-controlled trialROSEN, Lee S; GORDON, David; REITSMA, Dirk et al.Cancer. 2004, Vol 100, Num 12, pp 2613-2621, issn 0008-543X, 9 p.Article

Vandetanib Versus Placebo in Patients With Advanced Non―Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)JIN SOO LEE; HIRSH, Vera; PARK, Keunchil et al.Journal of clinical oncology. 2012, Vol 30, Num 10, pp 1114-1121, issn 0732-183X, 8 p.Article

Erlotinib in previously treated non-small-cell lung cancerSHEPHERD, Frances A; PEREIRA, José Rodrigues; VAN KOOTEN, Maximiliano et al.The New England journal of medicine. 2005, Vol 353, Num 2, pp 123-132, issn 0028-4793, 10 p.Article

Weekly paclitaxel and gemcitabine chemotherapy for metastatic non-small cell lung carcinoma (NSCLC): A dose-optimizing Phase II trialHIRSH, Vera; WHITTOM, Renaud; OFIARA, Linda et al.Cancer. 2003, Vol 97, Num 9, pp 2242-2247, issn 0008-543X, 6 p.Article

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST) : a randomised phase III trial. CommentaryCULLEN, Michael; THATCHER, Nicholas; SELLERS, Mark V et al.Lancet (British edition). 2008, Vol 372, Num 9652, issn 0140-6736, 1785-1786, 1809-1818 [12 p.]Article

Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trialHIRSH, Vera; WHITTOM, R; DESJARDINS, P et al.Lung cancer. 2004, Vol 46, Num 1, pp 113-118, issn 0169-5002, 6 p.Article

Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non- small-cell lung cancer: A phase III trial of the Italian gemvin investigators and the national Cancer institute of Canada clinical trials groupGRIDELLI, Cesare; GALLO, Ciro; FINDLAY, Brian et al.Journal of clinical oncology. 2003, Vol 21, Num 16, pp 3025-3034, issn 0732-183X, 10 p.Article

Could targeting bone delay cancer progression? Potential mechanisms of action of bisphosphonatesAFT, Rebecca; PEREZ, Jose-Ricardo; RAJE, Noopur et al.Critical reviews in oncology/hematology. 2012, Vol 82, Num 2, pp 233-248, issn 1040-8428, 16 p.Article

An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastasesSANDLER, Alan; HIRSH, Vera; RECK, Martin et al.Lung cancer. 2012, Vol 78, Num 1, pp 1-7, issn 0169-5002, 7 p.Article

Impact of EGFR Inhibitor in Non―Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-AnalysisCHEE KHOON LEE; BROWN, Chris; JEMELA ANNE OSORIO SANCHEZ et al.Journal of the National Cancer Institute. 2013, Vol 105, Num 9, pp 595-605, issn 0027-8874, 11 p.Article

Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non―Small-Cell Lung Cancer: Final Results of a Phase III TrialSOCINSKI, Mark A; BONDARENKO, Igor; IGLESIAS, Jose L et al.Journal of clinical oncology. 2012, Vol 30, Num 17, pp 2055-2062, issn 0732-183X, 8 p.Article

Zoledronic acid versus placebo in the treatment of skeletal metastases in Patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial-the Zoledronic acid lung cancer and other solid tumors study groupROSEN, Lee S; GORDON, David; REITSMA, Dirk et al.Journal of clinical oncology. 2003, Vol 21, Num 16, pp 3150-3157, issn 0732-183X, 8 p.Article

Flexible chemotherapy regimen with gemcitabine and vinorelbine for metastatic nonsmall cell lung carcinoma: A Phase II multicenter trialHIRSH, Vera; LANGLEBEN, Adrian; AYOUB, Joseph et al.Cancer. 2001, Vol 92, Num 4, pp 830-835, issn 0008-543XArticle

Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial)NEIL REAUME, M; LEIGHL, Natasha B; PERRONE, Francesco et al.Lung cancer. 2013, Vol 82, Num 1, pp 115-120, issn 0169-5002, 6 p.Article

Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma With EGFR MutationsYANG, James Chih-Hsin; HIRSH, Vera; PALMER, Michael et al.Journal of clinical oncology. 2013, Vol 31, Num 27, pp 3342-3350, issn 0732-183X, 9 p.Article

Randomized, Double-Blind Study of Denosumab Versus Zoledronic Acid in the Treatment of Bone Metastases in Patients With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple MyelomaHENRY, David H; COSTA, Luis; VON MOOS, Roger et al.Journal of clinical oncology. 2011, Vol 29, Num 9, pp 1125-1132, issn 0732-183X, 8 p.Article

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer : AVAiLRECK, Martin; VON PAWEL, Joachim; MANEGOLD, Christian et al.Journal of clinical oncology. 2009, Vol 27, Num 8, pp 1227-1234, issn 0732-183X, 8 p.Article

Sequential therapy with vinorelbine followed by gemcitabine in patients with metastatic non small cell lung cancer (NSCLC), performance status (PS) 2, or elderly with comorbidities- : a multicenter phase II trialHIRSH, Vera; LATREILLE, Jean; KREISMAN, Harvey et al.Lung cancer. 2005, Vol 49, Num 1, pp 117-123, issn 0169-5002, 7 p.Article

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung CancerSHAW, Alice T; KIM, Dong-Wan; WU, Yi-Long et al.The New England journal of medicine. 2013, Vol 368, Num 25, pp 2385-2394, issn 0028-4793, 10 p.Article

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR MutationsSEQUIST, Lecia V; YANG, James Chih-Hsin; SU, Wu-Chou et al.Journal of clinical oncology. 2013, Vol 31, Num 27, pp 3327-3334, issn 0732-183X, 8 p.Article

Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As FirstLine Treatment for Advanced Non―Small-Cell Lung CancerHIRSH, Vera; PAZ-ARES, Luis; BAJETTA, Emilio et al.Journal of clinical oncology. 2011, Vol 29, Num 19, pp 2667-2674, issn 0732-183X, 8 p.Article